公开(公告)号：US20240368096A1

公开(公告)日：2024-11-07

申请号：US18582877

申请日：2024-02-21

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Samuel BARTLETT ,  Joseph D. PANARESE ,  Sourav GHORAI ,  Nathaniel Thomas KENTON ,  Sean RAFFERTY ,  Jonathan THIELMAN ,  Peilin XU ,  Bin WANG ,  William CASSELS ,  Scott MITCHELL ,  Yat Sun OR

IPC: C07D285/36 ,  C07D417/04 ,  C07D417/12 ,  C07D513/04

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, which inhibit the cellular entry of hepatitis B virus (HBV) and/or hepatitis D virus (HDV) or interfere with the function of the life cycle of HBV and/or HDV and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV and/or HDV infection. The invention also relates to methods of treating an HBV and/or HDV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

公开(公告)号：US20240262828A1

公开(公告)日：2024-08-08

申请号：US18543151

申请日：2023-12-18

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Joseph D. PANARESE ,  Dexter DAVIS ,  Samuel BARTLETT ,  Katherine CHONG ,  Nathaniel Thomas KENTON ,  Yat Sun OR

IPC: C07D471/14 ,  A61K45/06

CPC classification number: C07D471/14 ,  A61K45/06

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, thereof:




which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

公开(公告)号：US20240360155A1

公开(公告)日：2024-10-31

申请号：US18584520

申请日：2024-02-22

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Brian C. SHOOK ,  In Jong KIM ,  Thomas P. BLAISDELL ,  Jianming YU ,  Joseph D. PANARESE ,  Yat Sun OR

IPC: C07D513/04 ,  A61K31/5513 ,  A61K31/56 ,  A61K31/58 ,  A61K45/06 ,  C07D243/16 ,  C07D413/12 ,  C07D413/14 ,  C07D417/14 ,  C07D471/08 ,  C07D491/048 ,  C07D495/04 ,  C07D498/08

CPC classification number: C07D513/04 ,  A61K31/5513 ,  A61K31/56 ,  A61K31/58 ,  A61K45/06 ,  C07D243/16 ,  C07D413/12 ,  C07D413/14 ,  C07D417/14 ,  C07D471/08 ,  C07D491/048 ,  C07D495/04 ,  C07D498/08

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof:




which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

公开(公告)号：US20240325409A1

公开(公告)日：2024-10-03

申请号：US18587048

申请日：2024-02-26

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Sean RAFFERTY ,  Sourav GHORAI ,  Nathaniel Thomas KENTON ,  Peilin XU ,  Samuel BARTLETT ,  Scott MITCHELL ,  Joseph D. PANARESE ,  Yat Sun OR

IPC: A61K31/554 ,  A61K45/06 ,  A61P31/20 ,  C07D513/04

CPC classification number: A61K31/554 ,  A61K45/06 ,  A61P31/20 ,  C07D513/04

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, thereof:




which inhibit the cellular entry of hepatitis B virus (HBV) and/or hepatitis D virus (HDV) or interfere with the function of the life cycle of HBV and/or HDV and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV and/or HDV infection. The invention also relates to methods of treating an HBV and/or HDV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.